- | Country : -
- | organs : -
- | Specialty : -
Extract
Primary Study Objective The primary objective of this study is to demonstrate non-inferiority of Decapeptyl SR 22.5mg to a standard 3-monthly LHRH agonist in maintaining biochemical castration (testosterone levels ≤0.5ng/mL) after 6 months’ treatment.
Inclusion criteria
- locally advanced and metastatic prostrate cancer